Tradestie Institutional Equity Comparison Engine
CLYM vs PLUR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (2โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while PLUR counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PLUR at 3.6x Forward P/E and -2454.5% operating margin (-15.8% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
PLUR
CLYM N/M vs PLUR 3.6x Fwd P/E
Growth & Margin Winner
CLYM
Op Margin 0.0% vs -2454.5% ยท YoY +0.0% vs -15.8%
Momentum & Technical Winner
CLYM
1Y +407.4% vs -78.8% ยท 52W Pos 48% vs 2%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap
$608.5M
1M Return
-0.92%
1Y Return
+407.37%
Forward P/E
N/M
Unified AI Score
45.7 / 100
HOLD
Tech 41.0
Fund 47.0
Flow 50.0
Mom 54.0
PLUR
US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap
$15.1M
1M Return
+11.09%
1Y Return
-78.78%
Forward P/E
3.6x
Unified AI Score
28.8 / 100
SELL
Tech 15.0
Fund 34.0
Flow 50.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CLYM +407.37%
PLUR -78.78%
Spread: +482.9 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CLYM TTM Op. Margin: 0.0%
PLUR TTM Op. Margin: -2454.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs PLUR. Trailing 12-month operating profitability (CLYM 0.0% vs PLUR -2454.5%) and valuation multiples (CLYM N/M vs PLUR 3.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CLYM | PLUR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $608.5M | $15.1M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | 3.6x | Lower Multiple | PLUR |
| Forward P/E Ratio Valuation | N/M | 3.6x | Lower Multiple | PLUR |
| Revenue Growth (YoY) Growth | +0.0% | -15.8% | Higher Growth | CLYM |
| Operating Margin (TTM) Profitability | 0.0% | -2454.5% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -29.3% | -1022.0% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 48% ($2โ$18) | 2% ($1โ$5) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 112% Vol | 0.80ฮฒ ยท 102% Vol | Lower Realized Risk | PLUR |
| Unified Institutional Score Composite Signal | 45.7 / 100 (HOLD) | 28.8 / 100 (SELL) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CLYM vs PLUR Buy Guide
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
PLUR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CLYM nor PLUR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.